Cargando…

Identification of a novel germline BRCA2 variant in a Chinese breast cancer family

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer‐related deaths in women worldwide. In this study, a large Chinese pedigree with breast cancer including a proband and two female patients was recruited and a familial history of breast cancer was collected by quest...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jingliang, Peng, Jiangzhou, Fu, Jiewen, Khan, Md. Asaduzzaman, Tan, Pingping, Wei, Chunli, Deng, Xiyun, Chen, Hanchun, Fu, Junjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991642/
https://www.ncbi.nlm.nih.gov/pubmed/31782247
http://dx.doi.org/10.1111/jcmm.14861
_version_ 1783492695986012160
author Cheng, Jingliang
Peng, Jiangzhou
Fu, Jiewen
Khan, Md. Asaduzzaman
Tan, Pingping
Wei, Chunli
Deng, Xiyun
Chen, Hanchun
Fu, Junjiang
author_facet Cheng, Jingliang
Peng, Jiangzhou
Fu, Jiewen
Khan, Md. Asaduzzaman
Tan, Pingping
Wei, Chunli
Deng, Xiyun
Chen, Hanchun
Fu, Junjiang
author_sort Cheng, Jingliang
collection PubMed
description Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer‐related deaths in women worldwide. In this study, a large Chinese pedigree with breast cancer including a proband and two female patients was recruited and a familial history of breast cancer was collected by questionnaire. Clinicopathological assessments and neoadjuvant therapy‐related information were obtained for the proband. Blood samples were taken, and gDNA was extracted. The BRCA1/2 and PALB2 genes were screened using next‐generation sequencing by a targeted gene panel. We have successfully identified a novel, germline heterozygous, missense mutation of the gene BRCA2: c.7007G>T, p.R2336L, which is likely to be pathogenic in the proband and her elder sister who both had breast cancer. Furthermore, the risk factors for developing breast cancer in this family are discussed. Thus, genetic counselling and long‐term follow‐up should be provided for this family of breast cancer patients as well as carriers carrying a germline variant of BRCA2: c.7007G>T (p.R2336L).
format Online
Article
Text
id pubmed-6991642
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69916422020-02-03 Identification of a novel germline BRCA2 variant in a Chinese breast cancer family Cheng, Jingliang Peng, Jiangzhou Fu, Jiewen Khan, Md. Asaduzzaman Tan, Pingping Wei, Chunli Deng, Xiyun Chen, Hanchun Fu, Junjiang J Cell Mol Med Original Articles Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer‐related deaths in women worldwide. In this study, a large Chinese pedigree with breast cancer including a proband and two female patients was recruited and a familial history of breast cancer was collected by questionnaire. Clinicopathological assessments and neoadjuvant therapy‐related information were obtained for the proband. Blood samples were taken, and gDNA was extracted. The BRCA1/2 and PALB2 genes were screened using next‐generation sequencing by a targeted gene panel. We have successfully identified a novel, germline heterozygous, missense mutation of the gene BRCA2: c.7007G>T, p.R2336L, which is likely to be pathogenic in the proband and her elder sister who both had breast cancer. Furthermore, the risk factors for developing breast cancer in this family are discussed. Thus, genetic counselling and long‐term follow‐up should be provided for this family of breast cancer patients as well as carriers carrying a germline variant of BRCA2: c.7007G>T (p.R2336L). John Wiley and Sons Inc. 2019-11-28 2020-01 /pmc/articles/PMC6991642/ /pubmed/31782247 http://dx.doi.org/10.1111/jcmm.14861 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Cheng, Jingliang
Peng, Jiangzhou
Fu, Jiewen
Khan, Md. Asaduzzaman
Tan, Pingping
Wei, Chunli
Deng, Xiyun
Chen, Hanchun
Fu, Junjiang
Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title_full Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title_fullStr Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title_full_unstemmed Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title_short Identification of a novel germline BRCA2 variant in a Chinese breast cancer family
title_sort identification of a novel germline brca2 variant in a chinese breast cancer family
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991642/
https://www.ncbi.nlm.nih.gov/pubmed/31782247
http://dx.doi.org/10.1111/jcmm.14861
work_keys_str_mv AT chengjingliang identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT pengjiangzhou identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT fujiewen identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT khanmdasaduzzaman identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT tanpingping identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT weichunli identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT dengxiyun identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT chenhanchun identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily
AT fujunjiang identificationofanovelgermlinebrca2variantinachinesebreastcancerfamily